Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00319
|
|||||
Drug Name |
Citalopram
|
|||||
Synonyms |
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile; 1,3-dihydro[3,4]benzofuran-5-carbonitrile; 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; AE-641/00603021; Akarin; Akarin (TN); Celapram; Celapram (TN); Celexa; Celexa (TN); Celius; Celius (TN); Ciazil; Ciazil (TN); Cilift; Cilift (TN); Cipram; Cipram (TN); Cipramil (TN); Ciprapine; Ciprapine (TN); Citabax; Citabax (TN); Citadur; Citadur (TN); Citalec; Citalec (TN); Citalopram (USP/INN); Citalopram [Celexa]; Citalopram [INN:BAN]; Citalopramum; Citalopramum [INN-Latin]; Citaxin (TN); Citol (TN); Citopam; Citopam (TN); Citox (TN); Citrol (TN); Cytalopram; Dalsan; Dalsan (TN); Humorup; Lu 10-171; Lu-10-171; Nitalapram; Oropram; Pramcit; Recital; Recital (TN); Seropram; Seropram (TN); Talam; Talam (TN); Talohexal; Temperax; Vodelax; Zentius; Zentius (TN); Zetalo; Zetalo (TN); [3H]Citalopram
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Depression [ICD11: 6A8Z] | Approved | [1] | |||
Therapeutic Class |
Antidepressants
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C20H21FN2O
|
|||||
Canonical SMILES |
CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
|
|||||
InChI |
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
|
|||||
InChIKey |
WSEQXVZVJXJVFP-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 59729-33-8
|
|||||
Pharmaceutical Properties | Molecular Weight | 324.4 | Topological Polar Surface Area | 36.3 | ||
Heavy Atom Count | 24 | Rotatable Bond Count | 5 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | |||
XLogP |
3.2
|
|||||
PubChem CID | ||||||
PubChem SID |
103177051
, 104170209
, 104301562
, 121362384
, 124570949
, 124749575
, 124879738
, 124879739
, 125353996
, 126440716
, 126525331
, 126630818
, 126657311
, 126666544
, 127275913
, 127275914
, 127275915
, 14826333
, 24723457
, 29221926
, 4445124
, 46508746
, 47656601
, 47730750
, 47879631
, 48253450
, 48415786
, 48493834
, 49699144
, 49985355
, 50104852
, 51092001
, 53788845
, 56313600
, 56413158
, 57321451
, 7978955
, 80123691
, 80953770
, 8151789
, 85209895
, 855965
, 85787315
, 87690083
, 90340852
, 92307844
, 92309285
, 92711474
, 9775
, 99418031
|
|||||
ChEBI ID |
ChEBI:3723
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [3] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | MRP1 | Transporter Info | Km = 1.99 microM | Human embryonic kidney cells (HEK293)-MRP1 | [2] | |
References | ||||||
1 | Citalopram was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol. 2010 Apr;30(2):116-25. | |||||
3 | Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53. | |||||
4 | ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med. 2013 May;127(3):579-86. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.